Conference Reports for NATAP

Back

EASL 2024 June 5-8, Milan, Italy     Clinical evidence for expanding the treatment guidelines - (07/04/24)   Experimental and clinical evidence for expanding HBV treatment guidelines - (07/04/24)   Effect of elafibranor on pruritus in primary biliary cholangitis: Symptom severity and quality of life measurements from the phase III ELATIVE® trial - (06/19/24)   Efficacy of elafibranor in primary biliary cholangitis: Results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial - (06/19/24)   Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial - (06/19/24)   Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the carnitine transporter OCTN2 and the mitochondrial carnitine shuttle - (06/19/24)   PPAR-delta activation with seladelpar regulates cholangiocyte inflammation - (06/19/24)   Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis (PBC): Interim Results for 2 Years From the ASSURE Study - (06/19/24)   Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results - (06/19/24)   Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE® trial - (06/19/24)   EASL 2024 Viral Hepatitis Wrap-Up - (06/19/24)   Validation of a Modified Pediatric Formulation of Sofosbuvir and Daclatasvir in Genotype-4 HCV-infected Children Weighing 17-35 Kg - (06/18/24)   Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis - (06/18/24)   Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration - (06/18/24)   Is hepatitis C screening based on risk factors enough in primary care setting? - (06/18/24)   Impact of a "one-stop" simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus(HCV) infection receiving Opioid-Substitute Therapy (OST) in Israel - A Real World Evidence, retrospective analysis - (06/18/24)   Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH - (06/18/24)   Evaluating the effectiveness and safety of tenofovir alafenamide fumarate for preventing mother to child transmission of hepatitis B virus - (06/18/24)   Efficacy and safety of tenofovir alafenamide fumarate in preventing HBV vertical transmission in high maternal viral load: a multi-centre, prospective cohort study - (06/18/24)   Off-treatment Outcomes After Discontinuing Tenofovir-based Treatment in Hepatitis B e Antigen-positive and Hepatitis B e Antigen-negative Patients With Chronic Hepatitis B Virus - (06/18/24)   Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends - (06/18/24)   Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B - (06/18/24)   Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis TAF Slices Serious Liver Outcomes 80% in People Without High ALT - Mark Mascolini (06/18/24)   Association Between Post-treatment ALT Elevation and Subsequent HBsAg Seroclearance in Chronic Hepatitis B Patients Stopping NUC Therapy - (06/18/24)   Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: Part 2 of the REEF-D study - (06/18/24)   Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment - (06/18/24)   HDV infection in Israel: Epidemiology and co-morbidities - (06/18/24)   Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants - (06/18/24)   Hepatic flares after nucleos (t)ide analogue cessation in HBeAg negative hepatitis B: results from the Nuc-Stop study - (06/17/24)   Progression and risk factors after treatment with tenofovir or entecavir for chronic hepatitis B based on a multistate modeling approach - (06/17/24)   Evaluation of a novel HBV DNA test from fingerstick capillary blood at the point-of-care as a tool to enhance clinical management - (06/17/24)   Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B - interim data of the OSPREY study - (06/17/24)   VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels - (06/17/24)   Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone - (06/17/24)   Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study - (06/17/24)   Therapeutic Vaccine (BRII-179 Plus siRNA (BRII-835) Stir T-Cell Response Tied to Lower HBsAg - Mark Mascolini (06/17/24)   Tenofovir-Based HBV Treatment Cuts HCC Risk After Several Years - Mark Mascolini (06/17/24)   Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989 - (06/17/24)   Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA) - (06/17/24)   Model Says Treating Only 75 of 1000 PWID 7.5% Would Eliminate HCV in This Group - Mark Mascolini (06/17/24)   A prospective, blinded multicenter US evaluation of a multi-analysis blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. New Simple Blood Test More Sensitive Than Ultrasound for Early HCC - Mark Mascolini (06/17/24)   Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients Good Outcomes With Liver Transplants From HCV Viremic and Nonviremic Donors - Mark Mascolini (06/17/24)   Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of the SIMPLIFY study - (06/17/24)   Long term outcome among HCV-infected people who use drugs (PWUD) successfully treated for HCV infection with Glecaprevir/ Pibrentasvir (G/P) - (06/17/24)   Absorption, Distribution, Metabolism and Excretion of [14C]-Bemnifosbuvir in Rats - (06/17/24)   Low Risk of Drug-Drug Interactions for Ruzasvir Based Upon In Vitro Metabolism and Transporter Interaction Studies - (06/17/24)   Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier - (06/14/24)   Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection - (06/14/24)   Long-term liver morbidity and mortality after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study HCV Cure With DAAs Improves Survival Regardless of HCC - Mark Mascolini (06/14/24)   Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV - (06/14/24)   When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection - (06/14/24)   A prospective, blinded, multicenter U.S. evaluation of a multi-analyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis - (06/14/24)   Age at Incident Cirrhosis in Individuals With Hepatitis C Virus Infection: A US Administrative Claims Analysis - (06/14/24)   Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016 - 2022 - (06/14/24)   Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR) - (06/14/24)   The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through Cost of Illness and Cost Consequence Analysis - (06/14/24)   Healthcare Resource Utilisation and Costs of Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection Across Disease States Among Hospitalised Adults in Italy - (06/14/24)   Bulevirtide Monotherapy Lowers Risk of Decompensation But Not HCC - Mark Mascolini (06/14/24)   The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia - (06/14/24)   Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study - (06/14/24)   Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment - (06/14/24)   Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants - (06/14/24)   Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood - (06/13/24)   Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood - Mark Mascolini (06/13/24)   Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis - (06/13/24)   No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study - (06/13/24)   Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301 - (06/13/24)   Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis - (06/13/24)   LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 120 WEEKS: A RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/13/24)   Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort - (06/13/24)   Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver - (06/13/24)   Unique Characteristics and Risk of Liver-Related Events Among Individuals With Hepatitis Delta Virus Infection With and Without Concurrent Hepatitis C Virus Infection: A United States Administrative Claims Data Analysis - (06/13/24)   Anti-HDV and HDV RNA Testing Rates for Hepatitis Delta Virus Among Adult Patients in the United States - (06/13/24)   Bulevirtide efficacy and safety in chronic hepatitis D patients on liver transplant waiting list for decompensated cirrhosis and/or hepatocellular carcinoma - (06/13/24)   High frequency of liver cirrhosis in European patients with hepatitis D: First data from a large multicentre study (D-SOLVE and HDV-1000 consortia) - (06/13/24)   Rapid Reductions of HDV RNA and ALT with the Monoclonal Antibody, BJT-778: Results from a Phase 2 Study - (06/13/24)   Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program - (06/12/24)   Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta - (06/12/24)   Bulevirtide Plus pegIFNα Superior to Bulevirtide Alone for Chronic HDV - Mark Mascolini (06/12/24)   Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy - (06/12/24)   Impact of Bulevirtide Given With or Without Nucleos(t)ide Analogues on 48-Week Virologic Outcomes in Patients With Chronic Hepatitis Delta Virus Infection - (06/12/24)   Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis - (06/12/24)   Development and Validation of CLDQ-MASH: A Disease-specific Health-related Quality of Life Instrument for Patients with MASH - (06/12/24)   Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD - (06/12/24)   Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis - (06/12/24)   Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis - (06/12/24)   The economic burden of MASLD and MASH in US, Japan, Germany......$300 billion+, $62 B direct healthcare costs, $250 billion productivity loss in USA - (06/12/24)   Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial - (06/12/24)   Structured exercise plus mediterranean diet intervention in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a randomized controlled trial. The EHmet-DIA study - (06/12/24)   Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial - (06/12/24)   Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial - (06/12/24)   Characteristics and risk of major adverse liver outcomes and major cardiovascular events among Swedish patients with diagnosed and high risk of metabolic dysfunction-associated steatohepatitis-a REVEAL-MASH study High Fibrotic NASH Index Predicts 20% 10-Year Cardio Event Risk - Mark Mascolini (06/12/24)   Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography - a multicenter cohort study of 10,920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) - (06/12/24)   Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare - (06/12/24)   VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels - (06/12/24)   siRNA (JNJ-3989)Plus NRTI and PD-1 Inhibitor Lower But Do Not Clear HBsAg: A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B - Interim results of the OCTOPUS-1 study - Mark Mascolini (06/12/24)   Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B - (06/12/24)   A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B - Interim results of the OCTOPUS-1 study - (06/12/24)   Improvement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Monotherapy - (06/11/24)   Bulevirtide Plus pegIFNα Superior to Bulevirtide Alone for Chronic HDV - Mark Mascolini (06/11/24)   Hepatitis Delta Virus Infection is Associated with Significantly Greater Incidence of Cirrhosis and Hepatic Decompensation in U.S. Veterans with Chronic Hepatitis B - (06/11/24)   Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D - (06/11/24)   48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204 - (06/11/24)   Long-term liver morbidity and mortality after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study HCV Cure With DAAs Improves Survival Regardless of HCC - written by Mark Mascolini (06/10/24)   Testing for hepatitis C virus infection in prisons in England: room for improvement. Only One Quarter Entering 3 Prisons in England Tested for HCV - written by Mark Mascolini (06/10/24)   What happens to HCV incidence after WHO elimination goal is met? Agent-based modeling predicts sustained availability of direct-acting antivirals among people who inject drugs (PWID) is required to prevent returning to pre-elimination levels - (06/10/24)   Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up - (06/10/24)   Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children - (06/10/24)   Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients - (06/10/24)   Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years - (06/10/24)   Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study - (06/10/24)   Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C: 31% with cirrhosis received DAA, 12% without cirrhosis 2013-2019 - (06/10/24)   Liver stiffness measurement before and after antiviral treatment for hepatitis C: results from an OST-based hepatology service facility - (06/10/24)   Hepatocellular carcinoma development post hepatitis C virus cure is associated with distinct changes in the dynamics of the soluble inflammatory milieu - (06/10/24)   Impact of Hepatitis C virus direct acting antivirals on HCC evolution - (06/10/24)   Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR) - (06/09/24)   Description of age, sex, and characteristics of Hepatitis C patients in the SVR10K study: A real-world SOF/VEL analysis performed across five global regions - (06/09/24)   Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antiviral agents: results of a long-term prospective study period - (06/09/24)   In the era of effective antiviral therapy, cured hepatitis C remains a main cause of HCC - (06/09/24)   Point of Care Hepatitis C Screening and Treatment Among People Who Use Drugs in New York City Addiction Centers: Barriers and Opportunities - (06/09/24)   Increasing Hepatitis C screening rates at a New York City primary care clinic: a continuation - (06/09/24)   Impact of direct acting antiviral market access policy barriers and restrictions for Hepatitis C (HCV) patients: a database analysis of claims from states with and without Medicaid restrictions - (06/09/24)   Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry - (06/09/24)   Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver - (06/08/24)   LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 120 WEEKS: A RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (06/08/24)   Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort - (06/08/24)